Shoji Sunao

Prof. Sunao Shoji is a board-certified urologist and professor with extensive clinical and research experience in prostate cancer diagnostics and minimally invasive therapies. He received his M.D. from Tokyo Medical University in 2002, followed by surgical residency at St. Luke’s International Hospital and urology training at Tokai University. He later completed a research fellowship at the University of Southern California (2011–2013) and earned an MBA in healthcare management from the International University of Health and Welfare in 2020. He has held multiple academic appointments at Tokai University, rising through the ranks to become Professor and Chairman of the Department of Urology in 2024. He also serves as Director of the Robotic Assisted Surgery Center at Tokai University Hospital. Prof. Shoji holds board certifications from the Japan Urological Association and the Japanese Cancer Therapy Society, and is certified in laparoscopic and robotic-assisted surgery as well as medical AI. His clinical expertise includes over 1,600 cases of MRI-TRUS fusion image-guided prostate biopsy and more than 450 cases of focal therapy using high-intensity focused ultrasound (HIFU) for localized prostate cancer. Prof. Shoji has received several academic distinctions, including Best Poster Awards from the American Urological Association and the World Congress of Endoscopic Surgery, as well as a Top 10 Abstract Award from the Engineering and Urology Society.

15th August 2025

Time	Session

13:30 15:00	Industry Symposium 3 【Sonablate】 Advancing Focal Therapy in Localized Prostate Cancer: From Patient Stratification to Post-HIFU Management Introduction and Welcome Po-Hui Chiang Taiwan Speaker Shoji SunaoJapan Speaker Update of Localized Prostate Cancer Therapy Yi-Hsiu HuangTaiwan Moderator Jen-Chieh ChenTaiwan Speaker Who is NOT the patient for Focal Therapy? Kae Jack Tay Singapore Moderator Vincent KhorMalaysia Speaker Oncological and Functional Outcomes of Focal Therapy Kuan-Chou ChenTaiwan Moderator Peter Ka-Fung ChiuHong Kong, China Speaker Minimal Invasive Therapy: Where do We Stand in 2025Endourological, Laparoscopic and robotic surgeries have replaced most open surgeries in Urology. Emergence of new robotic platforms have provided urologists with new opportunities. Both boom-type and module-type robots have been used, and they each have their strengths in practice. Tele-surgeries have provided a new paradigm of long-distance robotic surgeries to facilitate new surgical possibilities and proctorship. State of the art robotic surgeries in retrograde intrarenal surgeries and enbloc resection MDT Discussion: Personalizing Treatment in High Volume CSPCN/ADebate: Should We Only Offer Consolidative Cytoreductive Nephrectomy in Metastatic RCC?N/AFocal Therapy in Asia – Is It Prime Time?The increase in incidence of Prostate cancer has been rapid in Asia in the past 10 years. While Robotic radical prostatectomy and Radiotherapy has been the commonest treatments for localized prostate cancer, significant long-term morbidities are observed after surgery or radiotherapy including incontinence, erectile dysfunction and irradiation injury to the bladder and rectum. In the current era of MRI-guided prostate biopsy, focal diseases can be targeted and diagnosed, and image-guided focal therapy emerged as an alternative treatment. Although Focal therapy has a relatively higher rate of local recurrence, it has the advantages of minimal or no long-term complication after treatment, and it is possible to perform retreatment with focal therapy, prostatectomy or radiotherapy. In properly selected patients, the need for salvage prostatectomy or radiotherapy after focal therapy is less than 20% at 8 years, and patients’ quality of life could be preserved. In well-selected patients, focal therapy is an attractive option. Current focal therapy for prostate cancer available in Asia includes HIFU, Cryotherapy, Targeted Microwave Ablation (TMA), irreversible electroporation (IRE) and TULSA. Beyond Oncologic Control: Real-World Experience in Patient-Centered HIFU for Prostate Disease Shin-Hong ChenTaiwan Moderator L Sivaneswaran LechmiannandanMalaysia Speaker Follow-Up after HIFU Treatment Yu ChenTaiwan Moderator Po-Fan HsiehTaiwan Speaker Panel Discussion Mark EmbertonUnited Kingdom Moderator Shoji SunaoJapan Moderator Jacob See-Tong PangTaiwan Moderator Po-Hui Chiang Taiwan Moderator Closing Jacob See-Tong PangTaiwan Speaker TICC - 1F 101B

Time

Session

13:30

15:00

Industry Symposium 3 【Sonablate】

Advancing Focal Therapy in Localized Prostate Cancer: From Patient Stratification to Post-HIFU Management

Introduction and Welcome

Po-Hui Chiang Taiwan Speaker

Shoji SunaoJapan Speaker
Update of Localized Prostate Cancer Therapy

Yi-Hsiu HuangTaiwan Moderator

Jen-Chieh ChenTaiwan Speaker
Who is NOT the patient for Focal Therapy?

Kae Jack Tay Singapore Moderator

Vincent KhorMalaysia Speaker
Oncological and Functional Outcomes of Focal Therapy

Kuan-Chou ChenTaiwan Moderator

Peter Ka-Fung ChiuHong Kong, China Speaker Minimal Invasive Therapy: Where do We Stand in 2025Endourological, Laparoscopic and robotic surgeries have replaced most open surgeries in Urology. Emergence of new robotic platforms have provided urologists with new opportunities. Both boom-type and module-type robots have been used, and they each have their strengths in practice. Tele-surgeries have provided a new paradigm of long-distance robotic surgeries to facilitate new surgical possibilities and proctorship. State of the art robotic surgeries in retrograde intrarenal surgeries and enbloc resection MDT Discussion: Personalizing Treatment in High Volume CSPCN/ADebate: Should We Only Offer Consolidative Cytoreductive Nephrectomy in Metastatic RCC?N/AFocal Therapy in Asia – Is It Prime Time?The increase in incidence of Prostate cancer has been rapid in Asia in the past 10 years. While Robotic radical prostatectomy and Radiotherapy has been the commonest treatments for localized prostate cancer, significant long-term morbidities are observed after surgery or radiotherapy including incontinence, erectile dysfunction and irradiation injury to the bladder and rectum. In the current era of MRI-guided prostate biopsy, focal diseases can be targeted and diagnosed, and image-guided focal therapy emerged as an alternative treatment. Although Focal therapy has a relatively higher rate of local recurrence, it has the advantages of minimal or no long-term complication after treatment, and it is possible to perform retreatment with focal therapy, prostatectomy or radiotherapy. In properly selected patients, the need for salvage prostatectomy or radiotherapy after focal therapy is less than 20% at 8 years, and patients’ quality of life could be preserved. In well-selected patients, focal therapy is an attractive option. Current focal therapy for prostate cancer available in Asia includes HIFU, Cryotherapy, Targeted Microwave Ablation (TMA), irreversible electroporation (IRE) and TULSA.
Beyond Oncologic Control: Real-World Experience in Patient-Centered HIFU for Prostate Disease

Shin-Hong ChenTaiwan Moderator

L Sivaneswaran LechmiannandanMalaysia Speaker
Follow-Up after HIFU Treatment

Yu ChenTaiwan Moderator

Po-Fan HsiehTaiwan Speaker
Panel Discussion

Mark EmbertonUnited Kingdom Moderator

Shoji SunaoJapan Moderator

Jacob See-Tong PangTaiwan Moderator

Po-Hui Chiang Taiwan Moderator
Closing

Jacob See-Tong PangTaiwan Speaker

TICC - 1F 101B

16th August 2025

Time	Session

12:00 13:00	Luncheon Symposium 16【Sonablate】 Advancing Focal Therapy with HIFU for Localized Prostate Cancer Opening Mark EmbertonUnited Kingdom Moderator Jacob See-Tong PangTaiwan Moderator Preparing the Ground: Infrastructure Requirements Before Focal Therapy with HIFU Mark EmbertonUnited Kingdom Moderator Jacob See-Tong PangTaiwan Moderator Po-Fan HsiehTaiwan Speaker The Evolution of HIFU: Past, Present and Future Jacob See-Tong PangTaiwan Moderator Mark EmbertonUnited Kingdom Speaker Focal Therapy with HIFU for Localized Prostate Cancer: Innovations in Treatment Techniques and the Evolution of Therapeutic Technologies Mark EmbertonUnited Kingdom Moderator Jacob See-Tong PangTaiwan Moderator Shoji SunaoJapan Speaker Q & A Jacob See-Tong PangTaiwan Moderator Mark EmbertonUnited Kingdom Moderator TICC - 2F 201AF

Time

Session

12:00

13:00

Luncheon Symposium 16【Sonablate】

Advancing Focal Therapy with HIFU for Localized Prostate Cancer

Opening

Mark EmbertonUnited Kingdom Moderator

Jacob See-Tong PangTaiwan Moderator
Preparing the Ground: Infrastructure Requirements Before Focal Therapy with HIFU

Mark EmbertonUnited Kingdom Moderator

Jacob See-Tong PangTaiwan Moderator

Po-Fan HsiehTaiwan Speaker
The Evolution of HIFU: Past, Present and Future

Jacob See-Tong PangTaiwan Moderator

Mark EmbertonUnited Kingdom Speaker
Focal Therapy with HIFU for Localized Prostate Cancer: Innovations in Treatment Techniques and the Evolution of Therapeutic Technologies

Mark EmbertonUnited Kingdom Moderator

Jacob See-Tong PangTaiwan Moderator

Shoji SunaoJapan Speaker
Q & A

Jacob See-Tong PangTaiwan Moderator

Mark EmbertonUnited Kingdom Moderator

TICC - 2F 201AF